BHV-1400 Targets the non-immunosuppressive, selective depletion of circulating galactose-deficient Iga1 in Iga nephropathy, Biohaven Pharmaceuticals, Inc , Poster at the 4th Annual Targeted Protein Degradation Summit Europe, London, United Kingdom, March 19-21, 2024 (2024)
Also, issues related to the stability, bioavailability, and pharmacokinetics of supersulfide donors must be addressed to optimize their therapeutic efficacy and minimize potential side effects
Valles-ColomerMFalonyGDarziYTigchelaarEFWangJTitoRYet al
The content provided is for educational and informational purposes only and does not replace professional medical advice, diagnosis, or treatment.
The powdered form offers flexibility in dosing and application, making it a valuable tool for the comprehensive exploration of Dihexas potential in these domains